Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Whitehawk Therapeutics (WHWK) EBITDA (2018 - 2025)

Whitehawk Therapeutics (WHWK) has disclosed EBITDA for 8 consecutive years, with -$23.3 million as the latest value for Q4 2025.

  • Quarterly EBITDA fell 27.19% to -$23.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$20.5 million through Dec 2025, up 67.83% year-over-year, with the annual reading at -$20.5 million for FY2025, 67.83% up from the prior year.
  • EBITDA for Q4 2025 was -$23.3 million at Whitehawk Therapeutics, down from -$17.6 million in the prior quarter.
  • The five-year high for EBITDA was $73.0 million in Q1 2025, with the low at -$87.1 million in Q3 2021.
  • Average EBITDA over 5 years is -$16.1 million, with a median of -$16.2 million recorded in 2023.
  • The sharpest move saw EBITDA crashed 2674.39% in 2021, then surged 498.39% in 2025.
  • Over 5 years, EBITDA stood at -$16.6 million in 2021, then rose by 16.28% to -$13.9 million in 2022, then fell by 16.49% to -$16.2 million in 2023, then dropped by 12.76% to -$18.3 million in 2024, then dropped by 27.19% to -$23.3 million in 2025.
  • According to Business Quant data, EBITDA over the past three periods came in at -$23.3 million, -$17.6 million, and -$52.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.